AbbVie writes off $3.5B on Cerevel drug after Phase 2 failures

AbbVie is taking a major loss in the wake of its Cerevel buyout. AbbVie said it will write off $3.5 billion following two mid-stage failures for emraclidine, the experimental schizophrenia drug that was the centerpiece ...